Binge-Eating Disorder

The grounding supports a behavioral and psychological pattern of recurrent binge episodes with loss of control and associated negative emotions, but it does not provide a specific biological mechanism for binge-eating disorder. Review material highlights possible involvement of neuroendocrine signaling, including glucagon-like peptide 1, because GLP-1 receptor activation reduces food intake and body weight and dysregulation of the endogenous GLP-1 system is associated with binge eating. Psychedelic-assisted therapy is also discussed as a potential approach based on theorized effects on comorbid mood, trauma-related, and substance-use symptoms, but no definitive disease mechanism is established.

The supplied grounding does not support specific risk factors for binge-eating disorder. It does note that eating disorders often develop during adolescence or early adulthood and are more commonly diagnosed in young adult females, but this is stated for eating disorders overall rather than BED specifically. BED is also described as frequently co-occurring with other psychiatric disorders, which may increase clinical burden but is not presented as a causal risk factor.

The grounding indicates that treatment for eating disorders typically involves a combination of therapy, nutrition counseling, and medical care, but it does not provide BED-specific standard-of-care details. At the drug-class or modality level, the literature mentions pharmacotherapy research involving GLP-1 receptor agonists and preliminary studies or case reports of psychedelic-assisted therapy with ketamine, MDMA, psilocybin, and ayahuasca. These are described as emerging or potential approaches rather than established standard treatment for binge-eating disorder.